1.68 USD
▲+0.07+3.70%
盘后 1.64 +1.15%
2026-08-03
市值
$12.10M
市盈率
—
EPS
-1.07
股息率
—
52 周区间
1.35 – 4.20
成交量
38.59K
Beta
0.64
目标价
15.00
52W 低 1.3552W 高 4.20
价格走势
公司简介
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and i...